Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug-drug interaction of losartan and glimepiride metabolism by recombinant microsome CYP2C91, 2C93, 2C913, and 2C916 in vitro.

International journal of clinical pharmacology and therapeutics - 1 Sept 2014

Chen Sai-Zhen, Pan Pei-Pei, Shen Lei-Bin, Xu Shan-Shan, Dai Da-Peng, Geng Pei-Wu, Cai Jie, Cai Jian-Ping, Hu Guo-Xin

Abstract excerpt

OBJECTIVE: Co-administration of anti-hypertension and anti-diabetic drugs is common in clinical settings. METHODS: In this study, we characterized the drug-drug interactions of losartan (LOS) and glimepiride (GLP) using recombinant cytochrome P450 (CYP) 2C9 enzymes (CYP2C9*1, CYP2C9*3, CYP2C9*13, and CYP2C9*16). RESULTS: Metabolism of losartan by recombinant CYP2C9* 1, CYP2C9*3, CYP2C9*13, and CYP2C9* 16 was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin II Type 1 Receptor Blockers
Share to Biotransformation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Interactions

Share to Hydroxylation

Share to Hypoglycemic Agents

Share to Losartan

Share to Microsomes

Share to Sulfonylurea Compounds

Source

Identifiers

PMID: 24986093
DOI: 10.5414/CP202071

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug-drug interaction of losartan and glimepiride metabolism by recombinant microsome CYP2C9*1, 2C9*3, 2C9*13, and 2C9*16 in vitro.PMID 24986093Read ↗

In vitro assessment of 36 CYP2C9 allelic isoforms found in the Chinese population on the metabolism of glimepiride.Semantic proximity Read ↗

Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects.Semantic proximity Read ↗

Prediction of CYP-mediated silybin A-losartan pharmacokinetic interactions using physiological based pharmacokinetic modeling.Semantic proximity Read ↗

Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174.Semantic proximity Read ↗

Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects.Semantic proximity Read ↗

Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects.Semantic proximity Read ↗

Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals.Semantic proximity Read ↗

CYP2C9 genetic variants and losartan oxidation in a Turkish population.Semantic proximity Read ↗

The Role of CYP2C8 and CYP2C9 Genotypes in Losartan-Dependent Inhibition of Paclitaxel Metabolism in Human Liver Microsomes.Semantic proximity Read ↗

Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes.Semantic proximity Read ↗

[Association between cytochrome p4502c9 polymorphisms and losartan dosing in hypertensive patients].Semantic proximity Read ↗

Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.